ARTICLE | Management Tracks
Takeda’s Willemsen becomes CEO at Tessa
Plus new chief business officer at Standigm, and update from Biosion
August 23, 2022 12:21 AM UTC
Cell therapy company Tessa Therapeutics Ltd. named Thomas Willemsen as president and CEO, effective Oct. 1. Willemsen was most recently SVP of Asia Pacific at Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK), before which he held several roles at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Merck KGaA (Xetra:MRK). He also joins the board at Tessa. Tessa’s lead candidate, TT11, is an autologous CD30-CAR T therapy in Phase II studies for Hodgkin lymphoma.
Korean AI drug discovery company Standigm Inc. hired Carl Foster as chief business officer. Foster, who will be based in the U.S., was EVP of business development of Cempra Inc. and CEO of Jurilab Ltd., a genomics company...